Eric Jonasch, MD

Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.

The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.

Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.

Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.

The MD Anderson Cancer Center expert discussed next steps for those with von Hippel-Lindau disease–associated renal cell carcinoma being treated with the HIF-2a Inhibitor.

The HIF-2a Inhibitor, MK-6482, induced clinical responses among patients with von Hippel-Lindau disease–associated renal cell carcinoma.